干扰素β-1a-话题@MedSci - 梅斯（MedSci）

#干扰素β-1a#

8篇内容 | 1155人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1645942, encodeId=0163164594281, content=<a href='/topic/show?id=8d1d48e21de' target=_blank style='color:#2F92EE;'>#干扰素β-1a#</a>, objectTitle=Lancet respirat med：雾化吸入干扰素β-1a可大大改善新冠肺炎患者病情并加速恢复, objectType=article, longId=203344, objectId=2f45203344f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f45203344f4, replyNumber=0, likeNumber=0, createdTime=2021-04-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f45203344f4, moduleTitle=Lancet respirat med：雾化吸入干扰素β-1a可大大改善新冠肺炎患者病情并加速恢复, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2f45203344f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645944, encodeId=0a7e1645944e4, content=<a href='/topic/show?id=8d1d48e21de' target=_blank style='color:#2F92EE;'>#干扰素β-1a#</a>, objectTitle=NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者病情无显著改善作用, objectType=article, longId=207064, objectId=90bb20e064a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90bb20e064a9, replyNumber=0, likeNumber=89, createdTime=2021-07-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90bb20e064a9, moduleTitle=NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者病情无显著改善作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=90bb20e064a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645943, encodeId=dab6164594343, content=<a href='/topic/show?id=8d1d48e21de' target=_blank style='color:#2F92EE;'>#干扰素β-1a#</a>, objectTitle=NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者无明显治疗作用, objectType=article, longId=204094, objectId=9fe52040944a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fe52040944a, replyNumber=0, likeNumber=127, createdTime=2021-09-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fe52040944a, moduleTitle=NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者无明显治疗作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9fe52040944a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645941, encodeId=84501645941cb, content=<a href='/topic/show?id=8d1d48e21de' target=_blank style='color:#2F92EE;'>#干扰素β-1a#</a>, objectTitle=美国国立卫生研究院（NIH）进行瑞德西韦联合干扰素β-1a治疗COVID-19的临床试验, objectType=article, longId=198946, objectId=a877198946d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a877198946d5, replyNumber=0, likeNumber=77, createdTime=2021-06-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a877198946d5, moduleTitle=美国国立卫生研究院（NIH）进行瑞德西韦联合干扰素β-1a治疗COVID-19的临床试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a877198946d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645940, encodeId=b33d164594012, content=<a href='/topic/show?id=8d1d48e21de' target=_blank style='color:#2F92EE;'>#干扰素β-1a#</a>, objectTitle=NEJM：芬戈莫德与干扰素β-1a对儿童多发性硬化症的疗效比较, objectType=article, longId=148777, objectId=3e5c148e7712, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5c148e7712, replyNumber=0, likeNumber=107, createdTime=2018-10-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5c148e7712, moduleTitle=NEJM：芬戈莫德与干扰素β-1a对儿童多发性硬化症的疗效比较, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3e5c148e7712)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645939, encodeId=887e164593946, content=<a href='/topic/show?id=8d1d48e21de' target=_blank style='color:#2F92EE;'>#干扰素β-1a#</a>, objectTitle=NEJM：复发性多发性硬化症治疗奥瑞珠单抗与干扰素β-1a，哪家强？, objectType=article, longId=85090, objectId=262c8509025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262c8509025, replyNumber=0, likeNumber=62, createdTime=2017-01-28, rootId=0, userName=jklm17, userId=1dac23274520, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262c8509025, moduleTitle=NEJM：复发性多发性硬化症治疗奥瑞珠单抗与干扰素β-1a，哪家强？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=262c8509025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645938, encodeId=086b164593848, content=<a href='/topic/show?id=8d1d48e21de' target=_blank style='color:#2F92EE;'>#干扰素β-1a#</a>, objectTitle=ECTRIMS 2016：百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta疗效显著优于Avonex（干扰素β-1a）, objectType=article, longId=78356, objectId=ead2e8356ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ead2e8356ce, replyNumber=0, likeNumber=97, createdTime=2016-10-29, rootId=0, userName=jklm17, userId=1dac23274520, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ead2e8356ce, moduleTitle=ECTRIMS 2016：百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta疗效显著优于Avonex（干扰素β-1a）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ead2e8356ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645937, encodeId=ed05164593ed3, content=<a href='/topic/show?id=8d1d48e21de' target=_blank style='color:#2F92EE;'>#干扰素β-1a#</a>, objectTitle=干扰素β-1a早期治疗可控制MS进展（REFLEXION试验）, objectType=article, longId=5745, objectId=bbfa5e4508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbfa5e4508, replyNumber=0, likeNumber=115, createdTime=2013-04-02, rootId=0, userName=jklm17, userId=1dac23274520, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbfa5e4508, moduleTitle=干扰素β-1a早期治疗可控制MS进展（REFLEXION试验）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bbfa5e4508)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

干扰素β-1a

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#干扰素β-1a#

Lancet respirat med：雾化吸入干扰素β-1a可大大改善新冠肺炎患者病情并加速恢复

2021-04-10

智智灵药 (审核中...)

前往app查看评论内容

#干扰素β-1a#

NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者病情无显著改善作用

2021-07-11

智智灵药 (审核中...)

前往app查看评论内容

#干扰素β-1a#

NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者无明显治疗作用

2021-09-10

智智灵药 (审核中...)

前往app查看评论内容

#干扰素β-1a#

美国国立卫生研究院（NIH）进行瑞德西韦联合干扰素β-1a治疗COVID-19的临床试验

2021-06-22

智智灵药 (审核中...)

前往app查看评论内容

#干扰素β-1a#

NEJM：芬戈莫德与干扰素β-1a对儿童多发性硬化症的疗效比较

2018-10-17

jklm17 (审核中...)

前往app查看评论内容

#干扰素β-1a#

NEJM：复发性多发性硬化症治疗奥瑞珠单抗与干扰素β-1a，哪家强？

2017-01-28

jklm17 (审核中...)

前往app查看评论内容

#干扰素β-1a#

ECTRIMS 2016：百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta疗效显著优于Avonex（干扰素β-1a）

2016-10-29

jklm17 (审核中...)

前往app查看评论内容

#干扰素β-1a#

干扰素β-1a早期治疗可控制MS进展（REFLEXION试验）

2013-04-02

科室
- - 订阅+
  - 更多科室
工具
服务